“When you have a totally sales-motivated reason for doing CME, you should consider other options.”

The return on investment for CME should be measured more in terms of improving public health than increasing script sales, asserted panelist Mark Deitch during the Pharmaceutical Alliance for CME section meeting at the Alliance for CME's annual conference in January. How does Deitch convince his clients of the value of CME? For one thing, when Deitch, a 20-year medical educatio

Register to view the full article

Register for and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.

Already a member? .

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.